Biolase (BIOL) PT Lowered to $4 at Ascendiant Capital

Ascendiant Capital analyst Edward Woo lowered the price target on Biolase (NASDAQ: BIOL) to $4.00 (from $15.00) while maintaining a Buy rating.

The analyst comments "We believe BIOLASE is progressing (even if slow and lumpy at times) in its return to growth and profitability. We expect solid
improvement in 2024 (+4%) after a modest 2023 (+1%) and strong 2022 (+24%) which should drive momentum. BIOLASE has a solid line of innovative products, and should benefit from growth in the dental market, consistent sales execution, and new sales opportunities."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating